Supply Chain Intelligence

Lyell Immunopharma, Inc. Supply Chain

LYEL supply chain intelligence for Lyell Immunopharma, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

LYEL ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

2Suppliers
4Customers
3Debt Items
20Related Chains

Lyell Immunopharma, Inc. Suppliers

TickerNameConfidenceEvidence
JPM-PD JPMorgan Chase & Co. 72% sely affect our current and projected business operations and our financial condition and results of operations. Adverse developments that affect financial institutions, such as events involving liqu…
JPM-PD JPMorgan Chase & Co. 72% Reciprocal relationship from JPM-PD graph: Reciprocal relationship from LYEL graph: Reciprocal relationship from JPM-PD graph: Reciprocal relationship from LYEL graph: Reciprocal relationship from JP…

Lyell Immunopharma, Inc. Customers

TickerNameConfidenceEvidence
FRED-HUTCHINSON-CANCER-CENTER FRED-HUTCHINSON-CANCER-CENTER 92% In 2018, the Company entered into a research and collaboration agreement with Fred Hutchinson Cancer Center, pursuant to which it granted Fred Hutch rights to certain success payments.
JPM-PD JPMorgan Chase & Co. 72% sely affect our current and projected business operations and our financial condition and results of operations. Adverse developments that affect financial institutions, such as events involving liqu…
JPM-PD JPMorgan Chase & Co. 72% Reciprocal relationship from JPM-PD graph: Reciprocal relationship from LYEL graph: sely affect our current and projected business operations and our financial condition and results of operations. Ad…
TCRX TScan Therapeutics, Inc. 72% Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectivel…

Lyell Immunopharma, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
LYEL-DEBT Debt stack $39.5M 90% Market cache reports total debt of $39.5M.
LYEL-DEBT-10845 Warrants outstanding: 0 90% xbrl warrant detail from xbrl 2024-12-31.
LYEL-DEBT-10846 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-12-31.

Lyell Immunopharma, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Lyell Immunopharma, Inc..

Lyell Immunopharma, Inc. Ownership

HolderNameConfidenceEvidence
LYEL-OWNER-ARCH-VENTURE-MANAGEMENT-LLC ARCH Venture Management, LLC 90% 13F overlay lists ARCH Venture Management, LLC as top holder; 77 tracked holders.

Lyell Immunopharma, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
AUTL Autolus Therapeutics plc 100.00 2
JPM-PD JPMorgan Chase & Co. 100.00 1 ['customer', 'supplier']
TMO Thermo Fisher Scientific Inc. 100.00 2
MYGN Myriad Genetics, Inc. 100.00 2
DTIL Precision BioSciences, Inc. 100.00 2
RNAC Cartesian Therapeutics, Inc. 100.00 2
CRBU Caribou Biosciences, Inc. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
NVSEF Novartis AG 100.00 2
NTLA Intellia Therapeutics, Inc. 100.00 2
KYTX Kyverna Therapeutics, Inc. 100.00 2
BMY Bristol-Myers Squibb Company 100.00 2
BMYMP Bristol-Myers Squibb Co 100.00 2
IOVA Iovance Biotherapeutics, Inc. 100.00 2
IPSC Century Therapeutics, Inc. 100.00 2
TKPHF Takeda Pharmaceutical Company Limited 100.00 2
HOLX Hologic, Inc. 50.00 2
DLR Digital Realty Trust, Inc. 50.00 2
FATE Fate Therapeutics, Inc. 50.00 2
View LYEL supply chain intel →

Explore the full interactive supply chain map for Lyell Immunopharma, Inc..

Open LYEL supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map